USA flag logo/image

An Official Website of the United States Government

VACCINATION AGAINST IXODES SCAPULARIS TICK BITES

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
60572
Program Year/Program:
2002 / SBIR
Agency Tracking Number:
AI049651
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
L2 DIAGNOSTICS, LLC
BOX 8175 NEW HAVEN, CT -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2002
Title: VACCINATION AGAINST IXODES SCAPULARIS TICK BITES
Agency: HHS
Contract: 2R44AI049651-02
Award Amount: $748,024.00
 

Abstract:

DESCRIPTION (provided by applicant): Lyme disease is a multi-systemic infection caused by the pathogen Borrelia burgdorjeri. The black-legged tick, Ixodes scapularis, is the common vector for B. burgdorferi. This tick also transmits the agents of human granulocytic ehrlichiosis and babesiosis. The purpose of this project is to develop an anti-I. scapiilaris vaccine to block tick attachment and tick-mediated disease transmission. Rabbits or guinea pigs infested with I. scapularis acquire antibody-mediated resistance to tick bites, a phenomenon known as "tick-immunity.'' Phase I experiments evaluated Salp13 and Salp25D, two recombinant proteins expressed from I. scapularis salivary gland cDNAs, as candidate vaccines. Guinea pigs immunized with a combination of the two recombinant proteins demonstrated host resistance to tick bites. Phase II specific aims are to: (a) produce prototype Salp 13 and Salp25D vaccines suitable for extensive testing in animal models; (b) investigate Salp 13 and Salp25D contributions to the tick bite-induced tick immunity; and (c) determine if immunization with an optimized Salp13/Salp25D vaccine blocks pathogen transmission from ticks. These experiments will lead to Phase III development of a new vaccine designed to protect against multiple tick-borne pathogens. PROPOSED COMMERCIAL APPLICATION: A vaccine against Ixodes scapiilaris tick bites would potentially protect against several pathogens, including B. burgdorferi, Babesia microti, and the agent of human granulocytic ehrlichiosis. The commercial market would overlap with the market for LYMErix, a Glaxo SmithKline human Lyme disease vaccine, and the currently approved canine Lyme disease vaccines.

Principal Investigator:

Michel Ledizet

Business Contact:

Martin Mattessich
2033939439
MJMATT@IX.NETCOM.COM
Small Business Information at Submission:

L-TWO DIAGNOSTICS, LLC
L-TWO DIAGNOSTICS, LLC BOX 8175 NEW HAVEN, CT 94904

EIN/Tax ID: 061509946
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No